Multiple Myeloma
Conditions
Brief summary
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Interventions
OTHERObservational study - sample collection only.
No intervention - blood and/or bone marrow sample collection only
Sponsors
Royal Marsden NHS Foundation Trust
Institute of Cancer Research, United Kingdom
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder 2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment 3. Participants aged 18 years of age or above 4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling
Exclusion criteria
1. Participants unable to provide consent 2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cell viability | 12 months | Myeloma cell viability when incubated with standard of care and novel compounds. |
Countries
United Kingdom
Contacts
Primary ContactDisco Team
Outcome results
None listed